• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小 RNA 在调控胆管癌药物反应中的新作用。

The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma.

机构信息

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.

Department of Surgery and Liver Research Center, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.

出版信息

Biomolecules. 2020 Sep 30;10(10):1396. doi: 10.3390/biom10101396.

DOI:10.3390/biom10101396
PMID:33007962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7600158/
Abstract

Cholangiocarcinoma (CCA) is the most common biliary malignancy, and has a poor prognosis. The median overall survival with the standard-of-care chemotherapy (Gemcitabine and cisplatin) in patients with advanced-stage CCA is less than one year. The limited efficacy of chemotherapy or targeted therapy remains a major obstacle to improving survival. The mechanisms involved in drug resistance are complex. Research efforts focusing on the distinct molecular mechanisms underlying drug resistance should prompt the development of treatment strategies that overcome chemoresistance or targeted drug resistance. MicroRNAs (miRNAs) are a class of evolutionarily conserved, short noncoding RNAs regulating gene expression at the post-transcriptional level. Dysregulated miRNAs have been shown to participate in almost all CCA hallmarks, including cell proliferation, migration and invasion, apoptosis, and the epithelial-to-mesenchymal transition. Emerging evidence demonstrates that miRNAs play a role in regulating responses to chemotherapy and targeted therapy. Herein, we present an overview of the current knowledge on the miRNA-mediated regulatory mechanisms underlying drug resistance among CCA. We also discuss the application of miRNA-based therapeutics to CCA, providing the basis for innovative treatment approaches.

摘要

胆管癌(CCA)是最常见的胆道恶性肿瘤,预后不良。接受标准治疗化疗(吉西他滨和顺铂)的晚期 CCA 患者的中位总生存期不到一年。化疗或靶向治疗的疗效有限仍然是提高生存率的主要障碍。耐药机制复杂。专注于耐药性背后的不同分子机制的研究努力应该促使开发克服化疗耐药性或靶向药物耐药性的治疗策略。microRNAs(miRNAs)是一类进化上保守的短非编码 RNA,在转录后水平调节基因表达。失调的 miRNAs 已被证明参与几乎所有 CCA 的特征,包括细胞增殖、迁移和侵袭、细胞凋亡以及上皮-间充质转化。新出现的证据表明,miRNAs 在调节对化疗和靶向治疗的反应中发挥作用。本文综述了 miRNA 介导的耐药性调节机制在 CCA 中的研究现状。我们还讨论了 miRNA 治疗在 CCA 中的应用,为创新治疗方法提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3f/7600158/c55295332f80/biomolecules-10-01396-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3f/7600158/75198575ef92/biomolecules-10-01396-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3f/7600158/df06ee5317f9/biomolecules-10-01396-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3f/7600158/c55295332f80/biomolecules-10-01396-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3f/7600158/75198575ef92/biomolecules-10-01396-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3f/7600158/df06ee5317f9/biomolecules-10-01396-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3f/7600158/c55295332f80/biomolecules-10-01396-g003.jpg

相似文献

1
The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma.微小 RNA 在调控胆管癌药物反应中的新作用。
Biomolecules. 2020 Sep 30;10(10):1396. doi: 10.3390/biom10101396.
2
Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.长链非编码 RNA LINC00665 通过 miR-424-5p/BCL9L 轴调控 EMT 和干性特性促进胆管癌细胞对吉西他滨的耐药性。
Cell Death Dis. 2021 Jan 12;12(1):72. doi: 10.1038/s41419-020-03346-4.
3
Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.微小 RNA-130a-3p 通过 PPARG 调控胆管癌细胞对吉西他滨的耐药性。
Ann Surg Oncol. 2017 Aug;24(8):2344-2352. doi: 10.1245/s10434-017-5871-x. Epub 2017 May 30.
4
miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.miR-29b、miR-205 和 miR-221 增强 HuH28 人胆管癌细胞对吉西他滨的化疗敏感性。
PLoS One. 2013 Oct 17;8(10):e77623. doi: 10.1371/journal.pone.0077623. eCollection 2013.
5
The Role of microRNAs in Cholangiocarcinoma.微小 RNA 在胆管癌中的作用。
Int J Mol Sci. 2021 Jul 16;22(14):7627. doi: 10.3390/ijms22147627.
6
Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in Cholangiocarcinoma.蛋白质组学和生物信息学鉴定胆管癌中具有预后潜力的耐药相关基因。
Biomolecules. 2024 Aug 8;14(8):969. doi: 10.3390/biom14080969.
7
GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.阿替利珠单抗(apitolisib)联合吉西他滨和顺铂治疗可通过抑制 PI3K/Akt/mTOR 通路协同减少胆管癌细胞生长。
Biochem Biophys Res Commun. 2020 Sep 3;529(4):1242-1248. doi: 10.1016/j.bbrc.2020.06.011. Epub 2020 Aug 8.
8
Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.增强 ten-eleven translocation 1 的表达可逆转胆管癌对吉西他滨的耐药性,并降低 P-糖蛋白的表达。
Cancer Med. 2019 Mar;8(3):990-1003. doi: 10.1002/cam4.1983. Epub 2019 Feb 19.
9
MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.miR-206 通过抑制与基质 CAFs 的相互作用来抑制肝内胆管癌的恶化并提高对化疗的敏感性。
Int J Biol Sci. 2022 Jan 1;18(1):43-64. doi: 10.7150/ijbs.62602. eCollection 2022.
10
The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.酸性细胞外pH条件下OCT4的上调与胆管癌细胞系中吉西他滨耐药相关。
Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2745-2748. doi: 10.31557/APJCP.2019.20.9.2745.

引用本文的文献

1
Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing's Sarcoma: A Composite Review.微小 RNA 的癌基因谱作为尤文肉瘤治疗的新治疗靶点:综合综述。
Genes (Basel). 2023 Sep 23;14(10):1849. doi: 10.3390/genes14101849.
2
Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.黏蛋白 4 通过激活 AKT 赋予胆管癌患者吉西他滨耐药性和不良预后。
Int J Biol Sci. 2023 May 21;19(9):2772-2786. doi: 10.7150/ijbs.79126. eCollection 2023.
3
Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma.

本文引用的文献

1
The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.EPR 效应及超越:提高肿瘤靶向性和癌症纳米医学治疗效果的策略。
Theranostics. 2020 Jun 25;10(17):7921-7924. doi: 10.7150/thno.49577. eCollection 2020.
2
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.MRX34(一种脂质体 miR-34a 模拟物)治疗晚期实体瘤患者的 1 期研究。
Br J Cancer. 2020 May;122(11):1630-1637. doi: 10.1038/s41416-020-0802-1. Epub 2020 Apr 2.
3
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
嵌合免疫检查点蛋白疫苗抑制大鼠胆管癌的发生和生长。
Front Immunol. 2022 Oct 20;13:982196. doi: 10.3389/fimmu.2022.982196. eCollection 2022.
4
MiRNA-196-5p Promotes Proliferation and Migration in Cholangiocarcinoma via HAND1/Wnt/-Catenin Signaling Pathway.微小RNA-196-5p通过HAND1/ Wnt/β-连环蛋白信号通路促进胆管癌的增殖和迁移。
J Oncol. 2022 Apr 12;2022:4599676. doi: 10.1155/2022/4599676. eCollection 2022.
5
Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.胆管癌:遗传和表观遗传因素的作用;检查点抑制剂和免疫疗法的当前及未来治疗方法
Am J Transl Res. 2021 Dec 15;13(12):13246-13260. eCollection 2021.
6
Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial.探索吉西他滨耐药性晚期胆管癌生物标志物的前沿研究:从基础研究到临床试验。
Biomolecules. 2021 Nov 3;11(11):1626. doi: 10.3390/biom11111626.
7
Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum.胆管狭窄与胆管癌——解开诊断难题
Front Oncol. 2021 Sep 30;11:699401. doi: 10.3389/fonc.2021.699401. eCollection 2021.
8
Role of autophagy in cholangiocarcinoma: Pathophysiology and implications for therapy.自噬在胆管癌中的作用:病理生理学及治疗意义
World J Clin Cases. 2021 Aug 6;9(22):6234-6243. doi: 10.12998/wjcc.v9.i22.6234.
培米替尼治疗既往治疗过的局部晚期或转移性胆管癌:一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
4
Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.分子靶向治疗:在胆管癌中准备“黄金时间”。
J Hepatol. 2020 Jul;73(1):170-185. doi: 10.1016/j.jhep.2020.03.007. Epub 2020 Mar 12.
5
miR-106b exerts tumor suppressive functions in ovarian carcinoma by directly targeting ZBTB7A.微小RNA-106b通过直接靶向锌指蛋白7A在卵巢癌中发挥肿瘤抑制功能。
Minerva Med. 2021 Oct;112(5):657-658. doi: 10.23736/S0026-4806.20.06475-7. Epub 2020 Mar 12.
6
Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.全球范围内 1993 年至 2012 年内肝内和肝外胆管癌发病率的变化趋势。
Cancer. 2020 Jun 1;126(11):2666-2678. doi: 10.1002/cncr.32803. Epub 2020 Mar 4.
7
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.通过 microRNA 介导的重布线调控 CD133+细胞扩增来调节胆管癌化疗耐药性。
Hepatology. 2020 Sep;72(3):982-996. doi: 10.1002/hep.31094. Epub 2020 Sep 10.
8
Encapsulated microRNA by gemcitabine prodrug for cancer treatment.吉西他滨前药包封的 microRNA 用于癌症治疗。
J Control Release. 2019 Dec 28;316:317-330. doi: 10.1016/j.jconrel.2019.11.010. Epub 2019 Nov 13.
9
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效:来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
10
miR-138 mediates sorafenib-induced cell survival and is associated with poor prognosis in cholangiocarcinoma cells.miR-138介导索拉非尼诱导的细胞存活,并与胆管癌细胞的不良预后相关。
Clin Exp Pharmacol Physiol. 2020 Mar;47(3):459-465. doi: 10.1111/1440-1681.13205. Epub 2019 Nov 25.